Search

Panel 8: Vaccines and immunology

Review and highlight of the significant advances made towards vaccine development and understanding of the immunology of otitis media

Bacterial Reservoirs in the Middle Ear of Otitis-prone Children Are Associated With Repeat Ventilation Tube Insertion

Presence of bacterial otopathogen in the middle ear during ventilation tube insertion was a predictor of children at-risk of repeat ventilation tube insertion

High concentrations of middle ear antimicrobial peptides and proteins are associated with detection of middle ear pathogens in children with recurrent acute otitis media

Elevated antimicrobial proteins and peptides and cytokines in middle ear effusion are a marker of inflammation and bacterial persistence

The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: A case - Control study

Respiratory viruses, particularly respiratory syncytial virus and human metapneumovirus, are major contributors to pneumonia in Australian children

Dornase alfa as an adjunct therapy to treat chronic ear infections

Chris Glenn Lea-Ann Peter Ruth Brennan-Jones Pearson Kirkham Richmond Thornton PhD BA (Education) PhD Candidate PhD MBBS MRCP(UK) FRACP PhD Head, Ear

Evaluation of a bacterial therapy for prevention of respiratory infection including influenza and otitis media

Deborah Lea-Ann Peter Ruth Strickland Kirkham Richmond Thornton PhD PhD MBBS MRCP(UK) FRACP PhD Head, Pregnancy and Early Life Immunology Co-Head,

Pathogens on the rise: is impaired immunity the cause of chronic ear and chest infections?

Ruth Elke Peter Thornton Seppanen Richmond PhD BSc PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Program

Microbiological and immunological factors predicting surgical outcomes for chronic otitis media

Lea-Ann Peter Ruth Kirkham Richmond Thornton PhD MBBS MRCP(UK) FRACP PhD Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.